Regal Investment Advisors LLC Invests $3.50 Million in Elevance Health, Inc. $ELV

Regal Investment Advisors LLC acquired a new position in Elevance Health, Inc. (NYSE:ELV) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 10,838 shares of the company’s stock, valued at approximately $3,502,000.

Other large investors have also recently added to or reduced their stakes in the company. Nilsine Partners LLC boosted its position in Elevance Health by 1.5% during the 3rd quarter. Nilsine Partners LLC now owns 1,918 shares of the company’s stock worth $620,000 after acquiring an additional 29 shares during the period. HBK Sorce Advisory LLC grew its stake in shares of Elevance Health by 4.4% in the third quarter. HBK Sorce Advisory LLC now owns 743 shares of the company’s stock worth $260,000 after purchasing an additional 31 shares in the last quarter. Detalus Advisors LLC increased its holdings in shares of Elevance Health by 1.8% during the third quarter. Detalus Advisors LLC now owns 1,726 shares of the company’s stock valued at $558,000 after purchasing an additional 31 shares during the period. Forum Financial Management LP raised its stake in shares of Elevance Health by 1.1% during the third quarter. Forum Financial Management LP now owns 2,971 shares of the company’s stock valued at $960,000 after purchasing an additional 33 shares in the last quarter. Finally, Activest Wealth Management raised its stake in shares of Elevance Health by 66.7% during the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 34 shares in the last quarter. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Royal Bank Of Canada lowered shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price for the company. in a research report on Tuesday, February 3rd. Guggenheim dropped their price target on shares of Elevance Health from $414.00 to $396.00 and set a “buy” rating on the stock in a research report on Thursday, January 29th. Barclays reduced their price target on shares of Elevance Health from $404.00 to $393.00 and set an “overweight” rating for the company in a research note on Friday, January 30th. Mizuho decreased their price objective on shares of Elevance Health from $413.00 to $350.00 and set an “outperform” rating for the company in a report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $332.00 price objective on shares of Elevance Health in a research note on Thursday, January 29th. Twelve investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $387.40.

Elevance Health Price Performance

Shares of Elevance Health stock opened at $291.69 on Friday. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $458.75. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. The stock has a market cap of $64.38 billion, a PE ratio of 11.61, a price-to-earnings-growth ratio of 1.59 and a beta of 0.51. The company’s 50-day moving average price is $338.25 and its two-hundred day moving average price is $334.11.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating the consensus estimate of $3.10 by $0.23. The company had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The business’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter last year, the firm posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, sell-side analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be issued a dividend of $1.72 per share. The ex-dividend date is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a yield of 2.4%. Elevance Health’s payout ratio is 27.39%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.